Articles · Amandeep Singh, Ph.D. ·
Tech Providers or Biotechs? The Quest for an Optimal Business Model in AI Drug Discovery
An analysis of evolving business models in the AI-driven drug discovery landscape.
Tech Providers or Biotechs? The Quest for an Optimal Business Model in AI Drug Discovery
Over the past decade, AI-powered drug discovery has matured from a futuristic promise into a fast-growing sector with over 200 partnerships established between AI startups and more than 50 global pharmaceutical companies. Yet despite this momentum, one fundamental question continues to challenge the sector’s long-term viability: What is the optimal business model for AI drug discovery companies?
As this new breed of biotech pioneers grows in number, funding, and scientific ambition, they must navigate a strategic crossroads: Should they act as technology providers, supplying cutting-edge AI tools to pharma clients? Or should they build their own pipeline of proprietary therapeutics, evolving into full-fledged biotech companies?
The Two Diverging Paths: Platform vs Pipeline
The current landscape sees AI drug discovery companies falling into one of two dominant archetypes:
AI-Enabled Biotechs (Pipeline Owners):
These companies leverage AI to identify novel targets and design therapeutics, aiming to shepherd these candidates through preclinical and clinical development. In doing so, they mimic traditional biopharma players, shouldering the same risks and rewards. Examples include Insitro and Recursion Pharmaceuticals, both of which have embraced deep pipelines with in-house development capabilities.
The upside? If successful, this model offers outsized returns through licensing deals, asset sales, or full drug commercialization. However, the costs are enormous, timelines long, and the execution risk significant—especially in the notoriously uncertain world of clinical development.
AI Tech Providers (Platform Model):
Other companies choose to focus on their core strength: developing proprietary AI platforms that can be licensed to pharmaceutical partners. These platforms may assist with target identification, hit generation, lead optimization, or clinical trial design. This model provides faster revenue, often through milestone payments or SaaS-like agreements, and avoids the high cost of wet-lab operations.
The challenge here is differentiation and defensibility. Many companies claim to offer similar AI capabilities, and clients may view these tools as commoditized unless paired with unique datasets or biological insights.
Why the Decision Matters
The choice between being a platform provider or a pipeline-focused biotech is not just semantic—it has profound implications for how companies fundraise, hire, price services, partner with pharma, and ultimately position themselves for acquisition or IPO.
Platform companies may find it easier to achieve early revenue but may struggle with valuation ceilings and competitive moats.
Pipeline companies often command higher valuations when successful, but they must raise more capital and face a steeper regulatory climb.
Some firms, like Exscientia and BenevolentAI, have tried hybrid models, combining internal pipelines with tech licensing. While this offers optionality, it also requires significant capital and cross-functional talent—two things early-stage companies may lack.
Strategic Flexibility Is Key
One core insight from the article is that there is no one-size-fits-all solution. Each company must align its business model with:
Its technological maturity
The capital appetite and risk tolerance of its investors
The expertise of its leadership team
The competitive positioning in a rapidly evolving ecosystem
Companies like Valo Health, which has combined big data infrastructure with clinical-stage assets, or Relay Therapeutics, which began with a platform and transitioned to a pipeline-driven model, show that adaptability can be a powerful asset.
The Road Ahead
As AI drug discovery continues to evolve, companies must grapple with a dual identity—balancing the scientific rigor of biotech with the agility and scale of a tech company. With pharma partnerships, public market scrutiny, and regulatory frameworks all catching up to this new paradigm, strategic clarity will be essential. Those who can identify the right model—and pivot effectively as conditions change—will be the ones to define the future of AI in life sciences.
Final Thoughts:
AI in drug discovery is not just about algorithms—it’s about making critical business choices that determine whether innovation translates into impact. The quest for the right business model continues, and in many ways, it's the most important experiment these companies will ever run.
This summary is based on a longer article authored by our team and originally published in BiopharmaTrend. We invite you to read the full article there for a more in-depth perspective.